# EU-1-21-1560_public-assessment-report_20210701_20210701_celsunax-epar-public-assessment-report.pdf

EUROPEAN MEDICINES AGENCY
MEDICINES
HEALTH
SCIENCE
22 April 2021
EMA/323721/2021
Committee for Medicinal Products for Human Use (CHMP)
Assessment report
Celsunax
International non-proprietary name: ioflupane (123I)
Procedure No. EMEA/H/C/005135/0000
Note
Assessment report as adopted by the CHMP with all information of a commercially confidential nature
deleted.
Official address Domenico Scarlattilaan 6 . 1083 HS Amsterdam . The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000
An agency of the European Union
European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged.
Table of contents
1. Background information on the procedure
4
4
1.1. Submission of the dossier.
1.2. Steps taken for the assessment of the product.
5
2. Scientific discussion
6
2.1. Problem statement
6
2.2. Quality aspects
6
2.2.1. Introduction
6
2.2.2. Active Substance
7
2.2.3. Finished Medicinal Product
12
2.2.4. Discussion on chemical, pharmaceutical and biological aspects
17
2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects
18
2.2.6. Recommendations for future quality development.
18
2.3. Non-clinical aspects
18
2.3.1. Ecotoxicity/environmental risk assessment
18
2.3.2. Discussion on non-clinical aspects.
19
2.3.3. Conclusion on the non-clinical aspects
19
2.4. Clinical aspects
19
2.4.1. Introduction
19
2.4.2. Pharmacokinetics
20
2.4.3. Discussion on clinical aspects
20
2.4.4. Conclusions on the clinical aspects
20
2.5. Risk Management Plan
20
2.6. Pharmacovigilance
21
2.7. Product information
21
2.7.1. User consultation
21
3. Benefit-Risk Balance.
21
3.1. Conclusions
21
4. Recommendations
21
Assessment report
EMA/323721/2021
Page 2/23
